CLINICAL TRIALS PROFILE FOR COVID-19 VACCINE, MRNA

All Clinical Trials for covid-19 vaccine, mrna

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000105 ↗	Vaccination With Tetanus and KLH to Assess Immune Responses.	Terminated	Masonic Cancer Center, University of Minnesota		2002-07-01	The purpose of this study is to learn how the immune system works in response to vaccines. We will give the vaccines to subjects who have cancer but have not had treatment, and to patients who have had chemotherapy or stem cell transplant. Some patients will get vaccines while they are on treatments which boost the immune system (like the immune stimulating drug interleukin-2 or IL-2). Although we have safely treated many patients with immune boosting drugs, we do not yet know if they improve the body's immune system to respond better to a vaccine. Some healthy volunteers will also be given the vaccines in order to serve as control subjects to get a good measure of the normal immune response. We will compare the patients and the healthy volunteers to study how their immune systems respond to the vaccines. There are several different types of white cells in the blood. We are interested in immune cells in the blood called T-cells. These T-cells detect foreign substances in the body (like viruses and cancer cells). We are trying to learn more about how the body fights these foreign substances. Our goal is to develop cancer vaccines which would teach T-cells to detect and kill cancer cells better. We know that in healthy people the immune system effectively protects against recurrent virus infection. For example, that is why people only get "mono" (mononucleosis) once under normal circumstances. When the body is infected with the "mono" virus, the immune system remembers and prevents further infection. We are trying to use the immune system to prevent cancer relapse. To test this, we will give two vaccines which have been used to measure these immune responses. Blood samples will be studied from cancer patients and will be compared to similar samples from normal subjects.
NCT00000755 ↗	A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3	Completed	Genentech, Inc.	Phase 1	1969-12-31	To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
NCT00000755 ↗	A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3	Completed	Glaxo Wellcome	Phase 1	1969-12-31	To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
NCT00000755 ↗	A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To examine the response of HIV-1 infected patients to vaccination with gp120/HIV-1MN antigen. To determine the effect of antiretroviral therapy on vaccine responsiveness. Fifty percent of HIV-1 infected individuals remain symptom free for 8-12 years. It has been hypothesized that HIV-specific immune responses are responsible for the period of relative quiescence of viral replication. Recent studies suggest that these immune functions can be augmented by vaccination with HIV-derived antigens.
NCT00000820 ↗	A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	PRIMARY: To examine the effect of aldesleukin ( IL-2 ) on viral activity in the blood. To determine the safety of low-dose IL-2 in combination with antiretroviral therapy versus antiretroviral therapy alone. SECONDARY: To examine delayed type hypersensitivity responses to skin test antigens and antibody responses to protein and polysaccharide vaccines. The profound immune impairment that results from HIV-1 infection is due, at least in part, to the loss of CD4+ T cells and the cytokines these cells secrete, especially IL-2 and interferon-gamma. Antiretroviral agents do not directly address the problem of immune impairment. Replacement of IL-2 at nontoxic doses may prevent or delay clinical immunosuppression and its attendant opportunistic infections. Also, since patients with HIV-1 infection respond suboptimally to routine protein and polysaccharide immunizations, IL-2 may provide an adjuvant effect on vaccine responses.
NCT00000822 ↗	A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells	Completed	Bristol-Myers Squibb	Phase 1	1969-12-31	To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH reaction. To describe the durability of the immunogen in patients who respond to the first 7 injections when they are boosted every 8 weeks for an additional 6-12 months [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. To describe the ability of the immunogen to induce a response after an additional 6-12 months of injections among patients who did not respond to the first 7 injections [AS PER AMENDMENT 11/12/96: stratum 1 patients only]. HIV-specific cellular immune responses appear to play an important role in HIV disease progression since both T helper and cytotoxic function against HIV decrease with disease progression.

Clinical Trial Conditions for covid-19 vaccine, mrna

Condition Name

Condition Name for covid-19 vaccine, mrna
Intervention	Trials
Influenza	71
COVID-19	59
HIV Infections	45
Melanoma	42

Condition MeSH

Condition MeSH for covid-19 vaccine, mrna
Intervention	Trials
COVID-19	140
Influenza, Human	122
Melanoma	104
HIV Infections	71

Clinical Trial Locations for covid-19 vaccine, mrna

Trials by Country

Trials by Country for covid-19 vaccine, mrna
Location	Trials
France	90
Italy	75
Belgium	64
South Africa	60
Brazil	54

Trials by US State

Trials by US State for covid-19 vaccine, mrna
Location	Trials
Maryland	279
California	210
New York	201
Texas	193
Florida	156

Clinical Trial Progress for covid-19 vaccine, mrna

Clinical Trial Phase

Clinical Trial Phase for covid-19 vaccine, mrna
Clinical Trial Phase	Trials
PHASE4	20
PHASE3	8
PHASE2	36

Clinical Trial Status

Clinical Trial Status for covid-19 vaccine, mrna
Clinical Trial Phase	Trials
Completed	738
Recruiting	360
Not yet recruiting	193

Clinical Trial Sponsors for covid-19 vaccine, mrna

Sponsor Name

Sponsor Name for covid-19 vaccine, mrna
Sponsor	Trials
National Cancer Institute (NCI)	211
National Institute of Allergy and Infectious Diseases (NIAID)	185
GlaxoSmithKline	74

Sponsor Type

Sponsor Type for covid-19 vaccine, mrna
Sponsor	Trials
Other	1896
Industry	888
NIH	449

COVID-19 mRNA Vaccine: Clinical Trials Update, Market Analysis, and Future Outlook

Last updated: March 2, 2026

What is the current status of clinical trials for COVID-19 mRNA vaccines?

The primary developers of COVID-19 mRNA vaccines—Pfizer-BioNTech and Moderna—began their initial Phase 1 trials in mid-2020. Both expedited approval processes to establish safety, immunogenicity, and dosage. Ongoing Phase 3 trials covered tens of thousands of participants across multiple countries.

Pfizer-BioNTech (BNT162b2/Pfizer-BioNTech COVID-19 Vaccine)

• Phase 3 trials enrolled 43,000 participants globally.
• Data cutoff: December 2020.
• Efficacy: 95% in preventing symptomatic COVID-19.
• Emergency Use Authorization (EUA): Granted by FDA on December 11, 2020.
• Approval: Full FDA approval received August 23, 2021.

Moderna (mRNA-1273/Spikevax)

• Phase 3 trials enrolled approximately 30,000 participants.
• Data cutoff: November 2020.
• Efficacy: 94.1% in preventing symptomatic COVID-19.
• EUA: Granted by FDA on December 18, 2020.
• Full approval: Applied for in 2022; under review in various jurisdictions.

Additional Studies

• Variant efficacy: Both vaccines retain high efficacy against alpha and delta variants but show reduced effectiveness against omicron, prompting booster development.
• Booster data: Multiple booster doses have demonstrated increased antibody titers, with ongoing trials testing frequency and dosage.

Market Dynamics and Demand Drivers

Production Capacity and Supply

• Worldwide, Pfizer-Biotech and Moderna have scaled up manufacturing facilities, producing over 3 billion doses in 2022.
• Additional manufacturers, including Sinovac and BioNTech, scaled production for global distribution.

Regulatory Approvals and Usage

• United States: COVID-19 vaccines authorized for all individuals aged 6 months and above.
• European Union: Authorization granted for adults and children; booster programs underway.
• China: Developed Sinovac and Sinopharm's inactivated vaccines; mRNA vaccines are used to complement them.

Adoption and Administration

• Global vaccination rates surpassed 70% of the population in high-income countries.
• Booster campaigns administered in over 100 countries.
• Hesitancy and logistical issues remain barriers, especially in low-income regions.

Market Size and Revenue

Year	Estimated Global Market Size (USD)	Market Growth
2020	< $1 billion	N/A
2021	$20 billion	2,000% increase
2022	$35 billion	75% growth from 2021

Competitive Landscape

• Pfizer-BioNTech and Moderna dominate with over 90% of market share in developed countries.
• New entrants explore next-generation formulations, including multivalent vaccines and pan-coronavirus vaccines.

Market Projections and Future Trends

Short-term (2023-2025)

• Vaccine demand: Will decline as pandemic pressure eases but will remain significant for booster doses and new variants.
• New formulations: Focus on variant-specific and enhanced immunity vaccines.
• Regulatory pathways: Streamlined for next-generation vaccines and pediatric indications.

Long-term (2025 and beyond)

• Market stabilization: (Estimated ) annual revenue could reduce to mid-single-digit billions as COVID-19 becomes endemic.
• Novel vaccine platforms: Development of universal coronavirus vaccines will compete for market share.
• Global access: Increasing efforts to supply low-income countries with affordable vaccines will shape distribution strategies and market access.

Key Market Drivers

• Emergence of variants requiring updated vaccines.
• Booster campaigns extending vaccine efficacy.
• Government procurement agreements, especially in the U.S., EU, and Asia.
• Advances in vaccine technology reducing production costs and side effects.

Regulatory and Policy Factors Affecting Market Dynamics

• FDA and EMA approvals directly influence global vaccination efforts.
• WHO Emergency Use Listings enable international supply, especially to low-income regions.
• Patents and licensing agreements impact manufacturing scalability.
• Intellectual property waivers proposed in WTO negotiations could affect future vaccine development and commercialization.

Risks and Challenges

• Variant-driven vaccine efficacy reduction.
• Vaccine hesitancy and misinformation.
• Distribution inequities between high- and low-income countries.
• Potential for regulatory delays on next-generation vaccines.

Key Takeaways

• Clinical trials for leading mRNA COVID-19 vaccines demonstrated high efficacy, prompting rapid EUA and full approvals.
• Manufacturing efforts have scaled to over 3 billion doses annually, with Pfizer-BioNTech and Moderna leading the market.
• The current market is driven by booster campaigns, variant-specific vaccines, and efforts to vaccinate children and low-income regions.
• Demand is expected to decline post-2023, but vaccine development will continue focused on broader coronavirus protection.
• Regulatory and geopolitical factors significantly influence vaccine availability and market growth.

FAQs

1. What is the efficacy of current mRNA COVID-19 vaccines against new variants?
Both Pfizer-BioNTech and Moderna show reduced efficacy against omicron but maintain substantial protection against severe disease and hospitalization, especially with booster doses.

2. When are next-generation vaccines expected to be commercialized?
Expected within 12-24 months, pending regulatory review, with ongoing trials testing variant-specific and pan-coronavirus formulations.

3. How does the global supply chain impact vaccine availability?
Manufacturing capacity, raw material supply, and intellectual property rights influence distribution, especially in low-income regions lacking local production.

4. Will COVID-19 vaccines remain profitable for developers?
In the short term, yes, driven by booster demand and new formulations. Long-term profitability depends on vaccine market stabilization and competition.

5. How are governmental policies affecting the vaccine market?
Procurement commitments and regulatory approvals can accelerate or hinder supply, with strategic stockpiling and vaccination policies shaping demand.

---

References

1. Pfizer. (2022). Pfizer-BioNTech COVID-19 Vaccine Data | FDA. [Online] Available at: https://www.fda.gov/
2. Moderna. (2022). Moderna COVID-19 Vaccine Data | FDA. [Online] Available at: https://www.fda.gov/
3. World Health Organization. (2022). COVID-19 vaccine markets. [Online] Available at: https://www.who.int/
4. Statista. (2023). COVID-19 vaccine market revenue. [Online] Available at: https://www.statista.com/
5. U.S. Food and Drug Administration. (2022). Emergency Use Authorization and Approvals for COVID-19 Vaccines.